Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchPhthalocyaninePhthalocyanine (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

    
  
Phthalocyanine for COVID-19
4 studies from 47 scientists
5,245 patients in 1 country
Statistically significant lower risk for ICU, hospitalization, recovery, and viral clearance.
3 studies from 3 independent teams (all from the same country) show significant improvements.
COVID-19 Phthalocyanine studies. Jul 2024. c19early.org
0 0.5 1 1.5+ All studies 38% Mortality 85% Hospitalization 54% Cases 54% Viral clearance 51% RCTs 38% Prophylaxis 54% Early 29% Late 52% Favorsphthalocyanine Favorscontrol
Jul 24
Covid Analysis Phthalocyanine for COVID-19: real-time meta analysis of 4 studies
Statistically significant lower risk is seen for ICU admission, hospitalization, recovery, and viral clearance. 3 studies from 3 independent teams (all from the same country) show significant improvements. Meta analysis using the most ser..
Feb 19
Brito-Reia et al., Current Oral Health Reports, doi:10.1007/s40496-024-00368-1 Antiviral Mechanism and Clinical Benefits of Mouthwash Active Against SARS-CoV-2
Review of antiviral mechanisms and clinical benefits of mouthwashes for SARS-CoV-2, including chlorhexidine (CHX), cetylpyridinium chloride (CPC), ethyl lauroyl arginate (ELA), hydrogen peroxide (HP), povidone-iodine (PVP-I), and anionic..
Jun 23
2023
Colado Simão et al., German Medical Science GMS Publishing House, doi:10.3205/000321 Effect of phthalocyanine oral and nasal antiseptic solutions on the infectivity of SARS-CoV-2 in patients with COVID-19: a randomized controlled trial
51% improved viral clearance (p=0.008). RCT 75 patients in Brazil, showing significantly lower viral load with phthalocyanine mouthwash and nasal spray. The combination was more effective than mouthwash alone.
Jan 28
2022
Basu et al., medRxiv, doi:10.1101/2022.01.26.22269854 A model-based approach to improve intranasal sprays for respiratory viral infections
Computational fluid dynamics study of nasal spray administration in 2 subjects showing a 2 orders of magnitude improvement in nasopharyngeal drug delivery using a new "Improved Use" (IU) spray placement protocol compared to the ..
Dec 8
2021
Poleti et al., Journal of Evidence-Based Dental Practice, doi:10.1016/j.jebdp.2022.101777 (date from preprint) Use of mouthwash and dentifrice containing antimicrobial phthalocyanine derivative for the reduction of clinical symptoms of COVID-19: A randomized triple-blinded clinical trial
29% improved recovery (p=0.02). RCT 500 patients in Brazil, showing improved recovery with a phthalocyanine derivative mouthwash and toothpaste. Toothbrushing for 2 minutes, three times per day, and gargling/rising (5ml) for one minute, three times a day, for 7 days.
Nov 15
2021
Brito-Reia et al., German Medical Science GMS Publishing House, doi:10.3205/dgkh000426 (date from preprint) Population-based virucidal phthalocyanine gargling/rinsing protocol to reduce the risk of coronavirus disease-2019: a community trial
54% fewer cases (p=0.08). Comparison of two similar communities in Brazil, with one using a phthalocyanine derivative mouthwash, suggesting efficacy of the treatment in lowering COVID-19 cases. There was 54% lower risk of confirmed cases during the intervention in..
Oct 7
2021
da Silva Santos et al., Scientific Reports, doi:10.1038/s41598-021-99013-5 Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19: randomised trial
85% lower mortality (p=0.23), 92% lower ICU admission (p=0.02), and 54% lower hospitalization (p=0.03). RCT 41 patients in Brazil, 20 treated with a phthalocyanine derivative mouthwash, showing shorter hosptalization and lower ICU admission with treatment. One minute gargling/rinsing 5 times per day.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit